newsfilter
← Latest News
Business Wire·

Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

- Reported Positive GATHER2 Results for Avacincaptad Pegol in Geographic Atrophy - - Planned NDA Submission Moved Up to End of This Year - - Received Favorable Feedback from FDA on Intermediate AMD Development Plan